Guardant Health (GH)

• Market cap: $4.53B
• 1 day: -1.74%
• 5 days: -1.11%
• 1 month: 5.22%
• 3 months: 77.27%
• 6 months: 12.63%
• Year to date: 15.39%
• 1 year: 55.34%
• 5 years: -56.67%
• 10 years: 13.85%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 1,779

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

29% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 73

4.64% more ownership

Funds ownership: 98.16% [Q2] → 102.79% (+4.64%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

6% less funds holding

Funds holding: 280 [Q2] → 264 (-16) [Q3]

16% less capital invested

Capital invested by funds: $3.39B [Q2] → $2.84B (-$553M) [Q3]

20% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 54

62% less call options, than puts

Call options by funds: $21.3M | Put options by funds: $56M

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35 5% downside
• Avg. target: $40 10% upside
• High target: $50 36% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

JP Morgan Julia Qin 100% 1-year accuracy 5 / 5 met price target	36% upside $50	Overweight Maintained	7 Nov 2024
Goldman Sachs Matthew Sykes 60% 1-year accuracy 25 / 42 met price target	2% downside $36	Buy Maintained	7 Nov 2024
Bernstein Eve Burstein 57% 1-year accuracy 4 / 7 met price target	5% downside $35	Outperform Maintained	30 Oct 2024